Anzeige
Meldung des Tages: Lettland-Defence-Zertifikat! Diese Aktie öffnet die Tür zu bis zu 3 Mio. € Finanzierung

Azitra Aktie News

Aktie
WKN:  ISIN:  US05479L3024 US-Symbol:  AZTR
0,1676 $
-0,0104 $
-5,84%
0,14226 € 20.02.26
Depot/Watchlist
Marktkapitalisierung *
574,55 Tsd. €
Streubesitz
89,58%
KGV
-
Index-Zuordnung
-

Azitra News

19.02.26 - PR Newswire
Azitra, Inc. to Present at BIO Investment & Growth Summit
Azitra, Inc. to Present at BIO Investment & Growth Summit PR Newswire
06.02.26 - PR Newswire
Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting PR Newswire
07.01.26 - PR Newswire
Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference
Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference PR Newswire
17.12.25 - PR Newswire
Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American PR Newswire
24.11.25 - PR Newswire
Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules
Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules PR Newswire
12.11.25 - PR Newswire
Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates
Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates PR Newswire
07.11.25 - PR Newswire
Azitra, Inc. Addresses False Report Regarding Sale of Securities
Azitra, Inc. Addresses False Report Regarding Sale of Securities PR Newswire
20.10.25 - PR Newswire
Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris
Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris PR Newswire
03.10.25 - PR Newswire
Azitra Receives Notice of Non-Compliance from NYSE American
Azitra Receives Notice of Non-​Compliance from NYSE American PR Newswire
04.09.25 - PR Newswire
Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference PR Newswire
27.08.25 - PR Newswire
Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash
Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-​Associated Rash PR Newswire
11.08.25 - PR Newswire
Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates
Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates PR Newswire
11.08.25 - PR Newswire
Azitra, Inc. Announces Reverse Stock Split
Azitra, Inc. Announces Reverse Stock Split PR Newswire
17.06.25 - PR Newswire
Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome
Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome PR Newswire
10.06.25 - PR Newswire
Azitra, Inc. Announces Presentation at the 2025 BIO International Convention
Azitra, Inc. Announces Presentation at the 2025 BIO International Convention PR Newswire
14.05.25 - PR Newswire
Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash
Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-​Associated Rash PR Newswire
13.05.25 - PR Newswire
Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates
Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates PR Newswire
25.04.25 - PR Newswire
Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025
Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025 PR Newswire
24.04.25 - PR Newswire
Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline
Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline PR Newswire
12.03.25 - PR Newswire
Azitra to Present at Microbiome Times Partnering Forum
Azitra to Present at Microbiome Times Partnering Forum PR Newswire

Newssuche

Videos

newspaper
18.02.26 -2,76%
Technical Trading: Chance mit 82 Prozent Treffern
Rohöl Long Typ: Turbo Open End WKN: VH65XQ Hebel:6 Laufzeit: OpenEnd Einstieg: Market ... Mehr »
Anzeige

Aktie im Fokus

Breaking News
DiagnosTear Technologies Inc
0,268 €
+5,51%
DiagnosTear Technologies Inc Chart
TeaRx™ erobert Großbritannien im Sturm?!
Mehr zur Aktie »